These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 7744993)

  • 1. Immunoglobulins affecting thyroid growth: a continuing controversy.
    Brown RS
    J Clin Endocrinol Metab; 1995 May; 80(5):1506-8. PubMed ID: 7744993
    [No Abstract]   [Full Text] [Related]  

  • 2. [The immune and nonimmune genesis of goiter].
    Grigorie D
    Endocrinologie; 1990; 28(3-4):95-106. PubMed ID: 1983320
    [No Abstract]   [Full Text] [Related]  

  • 3. [Spontaneous hypothyroidism in 4 patients with Graves-Basedow disease].
    González-González A; Recio Cordova JM; Aznar Ondoño I; Del Monte Jarabo Bueno M
    Endocrinol Nutr; 2009 May; 56(5):273-6. PubMed ID: 19627750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Graves disease in pregnancy a risk for the child. Maternal TSH receptor antibodies can cause fetal and neonatal thyrotoxicosis].
    Roos M; Sjöberg O; Axelsson O; Karlsson FA
    Lakartidningen; 2008 Jan 16-22; 105(3):120-4. PubMed ID: 18290505
    [No Abstract]   [Full Text] [Related]  

  • 5. Identification of separate determinants on the thyrotropin receptor reactive with Graves' thyroid-stimulating antibodies and with thyroid-stimulating blocking antibodies in idiopathic myxedema: these determinants have no homologous sequence on gonadotropin receptors.
    Kosugi S; Ban T; Akamizu T; Kohn LD
    Mol Endocrinol; 1992 Feb; 6(2):168-80. PubMed ID: 1349156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The implications of "thyroid-growth-immunoglobulins" (TGI) for the understanding of sporadic nontoxic nodular goitre.
    Doniach D; Chiovato L; Hanafusa T; Bottazzo GF
    Springer Semin Immunopathol; 1982; 5(4):433-46. PubMed ID: 6131546
    [No Abstract]   [Full Text] [Related]  

  • 7. Thyrotropin receptor autoantibodies induce human thyroid cell growth and c-fos activation.
    Huber GK; Safirstein R; Neufeld D; Davies TF
    J Clin Endocrinol Metab; 1991 May; 72(5):1142-7. PubMed ID: 1850754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial changes in thyroid-stimulating antibody and thyrotropin binding inhibitor immunoglobulin at the time of postpartum occurrence of thyrotoxicosis in Graves' disease.
    Tamaki H; Amino N; Aozasa M; Mori M; Tanizawa O; Miyai K
    J Clin Endocrinol Metab; 1987 Aug; 65(2):324-30. PubMed ID: 2885336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffuse hyperplasia of the thyroid gland (Graves' disease).
    Thompson LD
    Ear Nose Throat J; 2007 Nov; 86(11):666-7. PubMed ID: 18225623
    [No Abstract]   [Full Text] [Related]  

  • 10. [The transformation of Basedow's struma into nodular goiter: a reason for recurrence of hyperthyroidism].
    Studer H; Huber G; Derwahl M; Frey P
    Schweiz Med Wochenschr; 1989 Feb; 119(7):203-8. PubMed ID: 2652283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nodular goiter with thyroid antibodies in chronic idiopathic urticaria.
    Agarwal M; Faas FH
    Dermatol Online J; 2014 May; 20(5):22644. PubMed ID: 24852782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contrasting activities of thyrotropin receptor antibodies in experimental models of Graves' disease induced by injection of transfected fibroblasts or deoxyribonucleic acid vaccination.
    Rao PV; Watson PF; Weetman AP; Carayanniotis G; Banga JP
    Endocrinology; 2003 Jan; 144(1):260-6. PubMed ID: 12488353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of immunological markers in Graves' disease.
    Mann K; Saller B; Hörmann R
    Exp Clin Endocrinol; 1991 May; 97(2-3):224-30. PubMed ID: 1680726
    [No Abstract]   [Full Text] [Related]  

  • 14. Autoimmunity of thyroid disease. With emphasis on Graves' disease.
    van Ouwerkerk BM; Krenning EP; Docter R; Benner R; Hennemann G
    Neth J Med; 1985; 28(1):32-9. PubMed ID: 2858065
    [No Abstract]   [Full Text] [Related]  

  • 15. Lower extremity manifestations of Graves' disease.
    Sauer P; Brandes B; Mahmarian RR
    J Foot Ankle Surg; 1995; 34(5):489-97. PubMed ID: 8590885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinico-immunological parallels in diffuse toxic goiter].
    Kuleshov EV; Diachuk IA; Deĭkalo IN; Gnatiuk MS
    Sov Med; 1986; (8):29-33. PubMed ID: 3490701
    [No Abstract]   [Full Text] [Related]  

  • 17. Autoimmune thyrotoxicosis: diagnostic challenges.
    Ponto KA; Kahaly GJ
    Am J Med; 2012 Sep; 125(9):S1. PubMed ID: 22938935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Morphological characteristics of the stroma of the goiter-altered thyroid].
    Vasilenko IV; Vecherko SE
    Sov Med; 1984; (6):28-32. PubMed ID: 6547784
    [No Abstract]   [Full Text] [Related]  

  • 19. [Cytologic differentiation between the autonomous and autoimmune type of diffuse hyperthyroid goiter: correlation with TSH receptor antibodies, microsomal antibodies and infiltrative ophthalmopathy].
    Smoje J; Bistrović D; Ugrai V; Gall D
    Lijec Vjesn; 1989 Dec; 111(12):437-9. PubMed ID: 2636304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of microsomal antibodies with the intensity of the intrathyroidal autoimmune process in Graves' disease.
    Paschke R; Vogg M; Swillens S; Usadel KH
    J Clin Endocrinol Metab; 1993 Oct; 77(4):939-43. PubMed ID: 8408468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.